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CC BY-NC-ND license (http://creativeBackground/purpose: Patients with leptomeningeal carcinomatosis (LC) from breast cancer is
generally resistant to systemic chemotherapy. Bevacizumab may increase intratumor concen-
tration of the chemotherapeutic agents through vascular normalization, although the overall
clinical benefit of bevacizumab for metastatic breast cancer is under debate.
Methods: Successful treatment of two breast cancer patients who developed LC after whole
brain irradiation treatment for the brain metastases is reported here. Both patients have re-
fractory disease to taxane and anthracycline, and both of them have disease progression under
intrathecal methotrexate treatment for LC.
Results: The two patients received systemic chemotherapy with bevacizumab (7.5 mg/kg infu-
sion on Day 1), cisplatin (80 mg/m2 infusion for 24 hours on Day 2), and etoposide (80 mg/m2
infusion for 2 hours on Days 2e4) at 21e28 day intervals. Both patients achieved best response
of negative cerebral spinal fluid cytology study and dramatic improvement of neurologic deficit
after treatment. Their overall survival after development of LC was 8 months and 7.5 months
respectively.
Conclusion: Bevacizumab plus etoposide and cisplatin might be a new option for breast cancer
patients with LC. Further prospective study is warranted.
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Although the breast cancer treatment aramentarium con-
tinues evolving, current median overall survival (OS) after
central nervous system (CNS) metastases for metastatic
breast cancer (MBC) remain dismal (median OS 3e9
months1e3) as compared with that of other metastases
(median OS 21.7e31.9 months4,5 for first line treatment).
Although both leptomeningeal carcinomatosis (LC) and
parenchymal brain metastases usually developed after MBC
patients had received two to three lines of systemic
chemotherapy6 for preexisting metastases, the survival
after development of LC in MBC patients is even worse than
parenchymal brain metastases (median OS 3e3.3
months).6,7
For parenchymal brain metastasis, whole brain radio-
therapy (WBRT),8,9 surgery,10 and stereotactic radio-
surgery9,11 are current standard treatments for parencymal
brain metastases. However, there is no standard treatment
for LC. WBRT and intrathecal chemotherapy12 are the only
two treatment options for LC. But, these two treatments
did not provide satisfactory prolongation of OS for patients
with LC. Seeking better treatments to improve OS patients
with LC are unmet medical needs.
In this report, we present two breast cancer patients
with LC successfully treated with bevacizumab, etoposide,
and cisplatin. We hope to provide potential new treatment
options for LC pateints after they failed current standard
WBRT.Materials and methods
This report is composed of two MBC patients who were both
refractory to several lines of modern chemotherapeutic
agents in a university hospital, progressed after whole brain
radiotherapy for CNS metastases and intrathecal chemo-
therapy for LC. At the time of their bevacizumab usage, the
United States (US) Food Drug and Administration (FDA) had
approved its indication in combination with taxane for MBC
in the US. In Taiwan, it was also only approved for MBC
treatment in combination with paclitaxel. Other combina-
tion regimens are not approved by either US FDA or the
government in Taiwan. We thoroughly explained the off-
label usage for the patients and obtained their informed
consents for agreement on this treatment.Results
These two patients with invasive ductal carcinoma of the
breast developed LC after systemic disease failing taxane
and anthracycline treatments. The first patient was a 36-
year-old female who had been diagnosed with estrogen
receptor-negative, progesterone receptor-negative, and
HER2-negative invasive ductal carcinoma during pregnancy
in 2006. The patient’s initial staging was T4N3M1 with lung,
bone, and mesenteric lymph node metastases. After three
cycles of chemotherapy with docetaxel (70 mg/m2), epi-
rubicin (70 mg/m2), and cyclophosphamide (500 mg/m2),
palliative breast lumpectomy and axillary lymph node
dissection were performed. Another three cycles ofdocetaxel/epirubicin/cyclophosphamide were given, and
an almost clinically complete response was achieved. After
local radiotherapy to the breast, maintenance therapy with
capecitabine was administered for w5 months, at which
time relapse of the disease in the breast, bone, and lung
was confirmed. Chemotherapy with vinorelbine and
cisplatin for six cycles was given, and a good partial
response was achieved. The patient then received main-
tenance therapy with oral cyclophosphamide and ura-
ciletegafur for 12 months until multiple brain metastases
developed in May 2007. WBRT was given with complete
resolution of the metastatic brain lesions on the follow-up
image study. Four months after radiotherapy, symptoms
of recurrence, such as headaches and leg weakness,
developed. LC without recurrence of brain parenchymal
metastases was noted by a brain magnetic resonance im-
aging (MRI) study. The diagnosis was further documented by
a cerebral spinal fluid (CSF) cytology study. Intraventricular
methotrexate was administered for six doses via an
implanted Ommaya reservoir with a transient response,
which was documented by a transient decrease in the CSF
cancer cell number and improvement in the neurologic
deficits. However, the patient’s consciousness deteriorated
into a comatose status (Glascow coma scale E1V1M2) 4
weeks after the start of intraventricular methotrexate
treatment. A brain computed tomography (CT) with
contrast showed multiple brain metastases with diffuse
leptomeningeal enhancement (Fig. 1A), and the CSF cyto-
logical analysis showed numerous cancer cells. Systemic
chemotherapy with bevacizumab (7.5 mg/kg infusion on
Day 1), cisplatin (80 mg/m2 infusion for 24 hours on Day 2),
and etoposide (80 mg/m2 infusion for 2 hours on Days 2e4)
at 21-day intervals were given. The patient’s level of con-
sciousness became clear 2 weeks after systemic chemo-
therapy. After two cycles of bevacizumab, cisplatin, and
etoposide (BEEP) treatment, the CSF cytology study showed
massive cell debris, and the Ommaya reservoir became
dysfunctional due to obstruction. The patient underwent a
reservoir revision and a subsequent ventricular-peritoneal
shunt creation. After four courses of chemotherapy,
contrast brain CT revealed decreased leptomeningeal
enhancement. However, precontrast brain CT scan (Fig. 1B)
revealed multiple curvilinear high-density signals along the
leptomeninges of the supratentorial gyri, indicating a
treatment effect resulted in calcification. The CSF study
during these four courses of treatment revealed minimal
cell debris with no viable tumor cell. The patient’s recur-
rent LC had resulted in loss of respiratory drive and hy-
percapnic respiratory failure contributing to her death. She
died 8 months after the diagnosis of LC.
The second patient was a 54-year-old woman diagnosed
with invasive ductal carcinoma of the right breast. The
initial staging at diagnosis was T3N3aM0, stage IIIc. The
estrogen receptor, progesterone receptor, and HER-2 status
were all negative. After breast conservation surgery and
axillary lymph node dissection, adjuvant epirubicin and
cyclophosphamide for four cycles followed by paclitaxel for
an additional four cycles were given. Adjuvant radiotherapy
up to 5000 Gy in 25 fractions was also applied. However,
cerebellar metastases manifesting as frequent vomiting and
headaches occurred 2 weeks after the completion of
adjuvant radiotherapy. Despite near-total tumor excision
Figure 1 (A) Brain CT with contrast: The patient was comatose before systemic chemotherapy. Diffuse leptomeningeal
enhancement indicates leptomeningeal carcinomatosis. (B) Brain CT without contrast: Leptomeningeal calcification after
chemotherapy. CT Z computed tomography.
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sent on the MRI performed 1 month after radiotherapy.
Stereotactic radiosurgery (1800 Gy) was added subse-
quently. The patient was then free of symptoms until
seizure attacked again 3 months later. A CSF study showed
LC and a skin biopsy yielded metastatic carcinoma. Intra-
thecal methotrexate was used twice a week for 6 months.
The CSF cytology demonstrated decreased cell counts from
>500 adenocarcinoma cells (Fig. 2A) to two cells in 1 mL of
CSF (Fig. 2B). However, despite the cytologic improvement,
the patient’s level of consciousness deteriorated again
(E4V4M4) with seizure activity needing valproic acid 800 mg
three times per day, and the MRI study showed disease
progression. Therefore, four cycles of treatment (bev-
acizumab, cisplatin, and etoposide) identical to the first
patient were given. There were no more seizures and the
patient’s level of consciousness improved (E4V4M6). The
patient succumbed to her disease without recurrent lep-
tomeningeal metastases; it was 7.5 months after the diag-
nosis of LC. Her death was most likely attributable either to
disease progression in her organs other than LC or aspira-
tion pneumonia.Figure 2 (A) Pap smear. (B) Liu’s stain of CSF cells under 400 ma
LC relapse (2A) and cellular debris (2B) after two cycles of BEEP. CDiscussion
There is lack of standard systemic treatment for CNS
metastasis, mainly due to the concern regarding poor drug
penetration through the bloodebrain barrier (BBB).13
However, high response rates are noted with initial thera-
pies of some chemotherapeutic agents for CNS metastasis
lesions, suggesting that the experience of poor clinical
response rate for these patients may also partly be due to
the late onset of brain metastases which have been re-
fractory to several lines of treatments. For example, eto-
poside and cisplatin have been used as frontline treatment
for breast cancer patients with brain metastasis. The
overall response rate of brain metastases was 39%, although
the median overall survival was only 31 weeks.14 There is a
case series report from Labidi et al15 which describes four
breast cancer patients with brain metastases successfully
treated with bevacizumab and paclitaxel. The duration of
response was reported to be between 6 and 11 months. The
treatment of LC is even more difficult, but receiving
chemotherapy or not is reported to be one of the most
important prognostic factors for LC patients.16 Breastgnification demonstrating numerous cancer cells at the time of
SF, cerebral spinal fluid; LC, leptomeningeal carcinomatosis.
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develop LC, although the incidence of LC in breast cancer
patients is approximately 5%.17 Compared to brain metas-
tases, in which WBRT or operation/stereotactic radio-
surgery for oligo-metastatic nodules have been
documented to be the standard treatment at present,
there are no guidelines for the treatment of patients
suffering from LC.18 The main obstacles in the treatment of
LC including the difficulty for traditional chemotherapeutic
agents to pass through the BBB, and the poor blood perfu-
sion in meningeal metastatic lesions.19 Intrathecal chemo-
therapy with methotrexate, cytarabine, or trastuzumab (in
Her2-positive disease) has been tried for breast cancer
patients with LC.12,20 However, the median survival was
around 12 weeks using the treatments mentioned above.7
Higher vascular endothelial growth factor (VEGF) in CSF
is considered to correlate with the disease extent and
poorer prognosis in LC patients.21,22 Bevacizumab is a hu-
manized antiVEGF monoclonal antibody, which might be
able to alter typical BBB breakdown patterns in LC pa-
tients23 and to act as a reasonable option in clearing VEGF
within CSF. In addition, bevacizumab might transiently
normalize tumor vasculature resulting in increased drug
penetration into the tumor.24,25 The schedule for combi-
nation of antiangiogenic agents and conventional therapies
would alter the efficacy of treatment, either
improving24e26 or worsening.27 When chemotherapy was
given 1e3 days after bevacizumab, its penetration into the
tumor was proved to be better than concomitant or 7 days
after bevacizumab in a neuroblastoma xenograft model.24
In our recent meta-analysis, combining bevacizumab with
a weekly chemotherapy schedule was associated with
greater progression-free survival in available randomized
trials.28 Although there is no other human study using the
same bevacizumab schedule in the normalization window,
our meta-analysis result has echoed the importance of
administrating chemotherapy in the vascular normalization
window when combined with bevacizumab in murine
models.25 This has led to the idea of administrating
chemotherapy 1 day after bevacizumab in this pilot study.
For fear of tumor bleeding, MBC patients with CNS me-
tastases were mostly excluded from previous randomized
bevacizumab studies.29e34 Data on the efficacy of bev-
acizumab in this subgroup of MBC patients are lacking.
Nevertheless, retrospective exploratory analysis for bev-
acizumab safety35 in patients with CNS metastases showed
low cerebral hemorrhage rate (0.8e3.3%) among the
different trial settings. Thus, CNS metastases should not be
regarded as a contra-indication for enrollment into bev-
acizumab trials.
As for our patients, LC refractory to intraventricular
methotrexate treatment was documented by either
contrast-enhanced CT of the brain or a CSF cytology study.
After treatment with bevacizumab, cisplatin, and etopo-
side, the neurologic deficits improved. Subsequent brain CT
demonstrated decreased leptomeningeal enhancement
with treatment-induced tumor bed calcification, and the
follow-up CSF cytology study showed a disappearance of
the cancer cells. In addition, bevacizumab was reported to
have caused remote microinfarctions of meningeal vessels
in a nonsmall cell lung cancer patient with LC, and end-
stage damage with severe hyalinization, focal dystrophiccalcifications, and loss of media were demonstrated.22
Therefore, meningeal calcifications in our patients may
have resulted from the treatment effect of either chemo-
therapy or bevacizumab. Although cisplatin and etoposide
might to some extent diffuse into the CSF space, the
response to chemotherapy, including cisplatin and etopo-
side, in LC is still dismal.36,37 The efficacy of chemotherapy
in LC relied on adequate drug concentrations in the CSF and
adequate blood perfusion in the leptomenigeal cancer le-
sions.7 With the vascular-disrupting effect of bev-
acizumab,38 more chemotherapeutic agents might be able
to reach the CSF space to achieve effective tumor killing.
Bevacizumab treatment has also been shown to increase
brain tumor perfusion,38 which might facilitate the delivery
of chemotherapeutic agents to the lesion. This is the first
pilot report in the literature to demonstrate effective
treatment using bevacizumab plus chemotherapeutic
agents in breast cancer patients with LC. We have evidence
for this based on the pre- and posttreatment brain CT scans
which showed decreased leptomeningeal seeding with cal-
cifications, and from the CSF cytology studies which showed
transient clearance of CSF cancer cells, as well as clinical
improvement of neurologic deficits. These two patients
survived > 8 months and 7.5 months, respectively, after LC
was detected, which is far longer than historic controls.
This result poses a possible role for bevacizumab in
potentiating the cytotoxic effect in breast cancer patients
with LC. Due to the initial efficacy of bevacizumab in
combination with etoposide plus cisplatin found in these
two patients, we started a Phase II trial to study the effi-
cacy of the regimen in MBC patients with brain and/or
leptomeningeal metastases in Taiwan (BEEP trial,
NCT01281696). The preliminary report39 showed promising
median progression free survival of 6.2 months and 77.2%
CNS response rate in the total 35 enrolled patients.
Currently, there are two ongoing clinical trials
(NCT0100417240 and NCT0128169639) focusing on the effi-
cacy of bevacizumab in metastatic breast cancer patients
with CNS metastases.
In conclusion, this report demonstrates potential roles
for bevacizumab in combination with etoposide and
cisplatin for leptomeningeal carcinomatosis, and might
shed light on the potential beneficial group that was over-
looked in previous bevacizumab studies for MBC. The clin-
ical benefit may be verified after completion of current
ongoing trials.References
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